Ebanga™ (ansuvimab-zykl, formerly mAb114) a human monoclonal antibody indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
On 21 December 2020, Ridgeback obtained FDA approval for Ebanga™. In July 2022, Ridgeback entered into an agreement with Emergent BioSolutions Inc. where Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga™ in the United States and Canada, and Ridgeback will serve as the global access partner for Ebanga™, ensuring it remains available to patients free of charge in Ebola-stricken countries.
More Information
For more information EBANGA™ including the U.S. Prescribing Information, please go to: www.EBANGA.com.
Recent Press
- Media / Reuters 08.19.2022
- Press Release / GlobeNewswire 07.07.2022
- Press Release / Business Wire 10.20.2021
Development Pipeline
(ansuvimab-zykl, mAb114)
Collaborations
Ridgeback would like to acknowledge and thank our collaborators on the EBANGA™ (ansuvimab-zykl, mAb114) development program:
